XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.24.3

Selected Balance Sheet Information | 9 Months Ended
--- | ---
Sep. 30, 2024
Selected balance sheet information |
Selected balance sheet information |
3. | Selected balance sheet information
Inventory consists of the following at: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
(in thousands) | ​ | 2024 | ​ | 2023
Raw material | ​ | $ | 6,531 | ​ | $ | 4,714
Work-in-process | ​ |  | 280 | ​ |  | 654
Finished goods | ​ |  | 5,081 | ​ |  | 5,615
​ | ​ | $ | 11,892 | ​ | $ | 10,983
​ Property and equipment, net consists of the following at: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
(in thousands) | ​ | 2024 | ​ | 2023
Office furniture and equipment | ​ | $ | 489 | ​ | $ | 402
Lab equipment | ​ |  | 2,835 | ​ |  | 2,721
Computer equipment and software | ​ |  | 972 | ​ |  | 776
Leasehold improvements | ​ |  | 543 | ​ |  | 98
Capital equipment in process | ​ |  | 1,021 | ​ |  | 554
​ | ​ |  | 5,860 | ​ |  | 4,551
Less: Accumulated depreciation and amortization | ​ |  | 3,229 | ​ |  | 2,788
​ | ​ | $ | 2,631 | ​ | $ | 1,763
​ Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $169,000 and $137,000 for the three months ended September 30, 2024 and 2023, respectively, and $441,000 and $393,000 for the nine months ended September 30, 2024 and 2023, respectively. ​ Accrued expenses consist of the following at: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
(in thousands) | ​ | 2024 | ​ | 2023
Bonuses | ​ | $ | 2,982 | ​ | $ | 3,335
Paid time off | ​ | ​ | 931 | ​ | ​ | 770
401(k) match | ​ | ​ | 876 | ​ | ​ | —
Customer rebates | ​ | ​ | 633 | ​ | ​ | 411
Accrued interest payable | ​ | ​ | 276 | ​ | ​ | 220
Operating lease liability, current portion | ​ | ​ | 275 | ​ | ​ | 231
Employee stock purchase plan | ​ | ​ | 274 | ​ | ​ | —
Clinical trial and other professional fees | ​ | ​ | 205 | ​ | ​ | 277
Taxes | ​ | ​ | 167 | ​ | ​ | 125
Other | ​ |  | 1,052 | ​ |  | 611
​ | ​ | $ | 7,671 | ​ | $ | 5,980
​

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration